Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.18
RMTI's Cash to Debt is ranked higher than
57% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. RMTI: 1.18 )
RMTI' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 1.18

Equity to Asset 0.02
RMTI's Equity to Asset is ranked lower than
59% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. RMTI: 0.02 )
RMTI' s 10-Year Equity to Asset Range
Min: -0.59   Max: 0.87
Current: 0.02

-0.59
0.87
F-Score: 2
Z-Score: -1.55
M-Score: -2.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -89.84
RMTI's Operating margin (%) is ranked lower than
54% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. RMTI: -89.84 )
RMTI' s 10-Year Operating margin (%) Range
Min: -108.87   Max: 2.28
Current: -89.84

-108.87
2.28
Net-margin (%) -93.13
RMTI's Net-margin (%) is ranked lower than
54% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. RMTI: -93.13 )
RMTI' s 10-Year Net-margin (%) Range
Min: -108.39   Max: 1.18
Current: -93.13

-108.39
1.18
ROE (%) -8198.82
RMTI's ROE (%) is ranked lower than
61% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. RMTI: -8198.82 )
RMTI' s 10-Year ROE (%) Range
Min: -8198.82   Max: 6.19
Current: -8198.82

-8198.82
6.19
ROA (%) -134.16
RMTI's ROA (%) is ranked lower than
59% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. RMTI: -134.16 )
RMTI' s 10-Year ROA (%) Range
Min: -317.31   Max: 2.75
Current: -134.16

-317.31
2.75
ROC (Joel Greenblatt) (%) -2853.79
RMTI's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. RMTI: -2853.79 )
RMTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2920.45   Max: 11.67
Current: -2853.79

-2920.45
11.67
Revenue Growth (%) -23.00
RMTI's Revenue Growth (%) is ranked lower than
51% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. RMTI: -23.00 )
RMTI' s 10-Year Revenue Growth (%) Range
Min: -23   Max: 36.8
Current: -23

-23
36.8
EBITDA Growth (%) 159.60
RMTI's EBITDA Growth (%) is ranked higher than
99% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. RMTI: 159.60 )
RMTI' s 10-Year EBITDA Growth (%) Range
Min: -36.2   Max: 159.6
Current: 159.6

-36.2
159.6
EPS Growth (%) 109.90
RMTI's EPS Growth (%) is ranked higher than
99% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. RMTI: 109.90 )
RMTI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 109.9
Current: 109.9

0
109.9
» RMTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RMTI Guru Trades in

RMTI Guru Trades in

Q2 2013

RMTI Guru Trades in Q2 2013

Jim Simons 185,628 sh (New)
» More
Q3 2013

RMTI Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RMTI



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1071.00
RMTI's P/B is ranked lower than
80% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. RMTI: 1071.00 )
RMTI' s 10-Year P/B Range
Min: 1.73   Max: 1425
Current: 1071

1.73
1425
P/S 6.70
RMTI's P/S is ranked lower than
74% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. RMTI: 6.70 )
RMTI' s 10-Year P/S Range
Min: 0.47   Max: 8.48
Current: 6.7

0.47
8.48
EV-to-EBIT 250.00
RMTI's EV-to-EBIT is ranked lower than
78% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. RMTI: 250.00 )
RMTI' s 10-Year EV-to-EBIT Range
Min: 28.1   Max: 232.9
Current: 250

28.1
232.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.40
RMTI's Price/Median PS Value is ranked lower than
77% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. RMTI: 3.40 )
RMTI' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 3.34
Current: 3.4

0.22
3.34
Earnings Yield (Greenblatt) 0.40
RMTI's Earnings Yield (Greenblatt) is ranked lower than
67% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. RMTI: 0.40 )
RMTI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 3.6
Current: 0.4

0.4
3.6
Forward Rate of Return (Yacktman) 79.36
RMTI's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. RMTI: 79.36 )
RMTI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13   Max: -2.6
Current: 79.36

-13
-2.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:RWM.Germany
Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease ('ESRD') and chronic kidney disease ('CKD') with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 92% of its revenue and consist of two products known in the industry as 'acid' and 'bicarbonate' and are packaged as liquid or powder. All of its products are manufactured according to AAMI and GMP guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water (AMII standard). RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. teriLyte bicarbonate is sold in liquid form and is used mainly in acute care settings. It offer a range of ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is US based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, principally the FDA and corresponding state and foreign agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide